yttrium radioisotopes has been researched along with Adrenal Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chua, WM; Huang, HL; Lam, WW; Loh, LM; Loke, KSH; Ng, DC; Ong, SYK; Tai, D; Tang, CYL; Tham, WY; Yan, SX | 1 |
| Bongiovanni, A; Cittanti, C; Di Iorio, V; Di Mauro, F; Ferrara, M; Ibrahim, T; Lolli, I; Mezzenga, E; Nicolini, S; Paganelli, G; Sansovini, M; Scarpi, E; Severi, S; Tardelli, E; Zovato, S | 1 |
| Caplin, M; Cheung, VTF; Khoo, B; Nastos, K; Navalkissoor, S; Quigley, AM; Toumpanakis, C | 1 |
1 review(s) available for yttrium radioisotopes and Adrenal Cancer
| Article | Year |
|---|---|
Safety and efficacy of peptide receptor radionuclide therapy in patients with advanced pheochromocytoma and paraganglioma: A single-institution experience and review of the literature.
Topics: Adrenal Gland Neoplasms; Humans; Paraganglioma; Pheochromocytoma; Receptors, Peptide; Retrospective Studies; Yttrium Radioisotopes | 2023 |
1 trial(s) available for yttrium radioisotopes and Adrenal Cancer
| Article | Year |
|---|---|
Peptide receptor radionuclide therapy in patients with metastatic progressive pheochromocytoma and paraganglioma: long-term toxicity, efficacy and prognostic biomarker data of phase II clinical trials.
Topics: Adrenal Gland Neoplasms; Biomarkers; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Paraganglioma; Pheochromocytoma; Positron Emission Tomography Computed Tomography; Prognosis; Receptors, Somatostatin; Yttrium Radioisotopes | 2021 |
1 other study(ies) available for yttrium radioisotopes and Adrenal Cancer
| Article | Year |
|---|---|
Peptide Receptor Radionuclide Treatment and (131)I-MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas.
Topics: 3-Iodobenzylguanidine; Acute Kidney Injury; Adrenal Gland Neoplasms; Adult; Aged; Chemotherapy, Adjuvant; Female; Humans; Male; Middle Aged; Octreotide; Organometallic Compounds; Paraganglioma; Pheochromocytoma; Radiopharmaceuticals; Retrospective Studies; Yttrium Radioisotopes | 2017 |